Although ADI-PEG20 has shown promising efficacy in ASS1-deficient breast cancer cells, resistance to ADI in some ASS1-overexpressing breast cancer cell lines remains a challenge for ADI-based therapy. This evidence concerns the gene ASS1 and breast carcinoma.